ArticleJournal of personalized medicine2022
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment.
Nicola Personeni et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.